Open AccessPhage Lytic Enzyme Cpl‐1 for Antibacterial Therapy in Experimental Pneumococcal Meningitis
Author(s) -
Denis Grandgirard,
Jutta M. Loeffler,
Vincent A. Fischetti,
Stephen L. Leib
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/587942
Subject(s) - streptococcus pneumoniae , lytic cycle , meningitis , microbiology and biotechnology , antibiotics , medicine , cerebrospinal fluid , antimicrobial , phage therapy , bacterial meningitis , pneumococcal infections , bacteriophage , virology , biology , virus , surgery , escherichia coli , biochemistry , gene
Treatment of bacterial meningitis caused by Streptococcus pneumoniae is increasingly difficult, because of emerging resistance to antibiotics. Recombinant Cpl-1, a phage lysin specific for S. pneumoniae, was evaluated for antimicrobial therapy in experimental pneumococcal meningitis using infant Wistar rats. A single intracisternal injection (20 mg/kg) of Cpl-1 resulted in a rapid (within 30 min) decrease in pneumococci in cerebrospinal fluid (CSF) by 3 orders of magnitude lasting for 2 h. Intraperitoneal administration of Cpl-1 (200 mg/kg) led to an antibacterial effect in CSF of 2 orders of magnitude for 3 h. Cpl-1 may hold promise as an alternative treatment option in pneumococcal meningitis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom